Arsenic trioxide activate transcription of heme oxygenase-1 by promoting nuclear translocation of NFE2L2

International Journal of Medical Sciences

Volumn 12, Issue 8, 2015, Pages 674-679

  Yue, Zhen ^a   Zhong, Lingzhi ^a,c   Mou, Yan ^a,b   Wang, Xiaotong ^a   Zhang, Haiying ^a   Wang, Yang ^a   Xia, Jianxin ^b   Li, Ronggui ^a   Wang, Zonggui ^b  

^a Basic Medical College   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Arsenic trioxide; Heme oxygenase 1; Nuclear factor erythroid 2 like 2; Nuclear translocation; Osteosarcoma

Indexed keywords

ARSENIC TRIOXIDE; DACTINOMYCIN; HEME OXYGENASE 1; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; HMOX1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INDUCTION; HEME OXYGENASE 1 GENE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OSTEOSARCOMA CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; CELL NUCLEUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; METABOLISM; OSTEOSARCOMA; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; IMMUNOHISTOCHEMISTRY; NF-E2-RELATED FACTOR 2; OSTEOSARCOMA; OXIDES; TRANSCRIPTION, GENETIC;

EID: 84938869151     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.12450     Document Type: Article

References (28)

1. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010; 5: 78-87.
2. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007; 19: 341-6.
3. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009; 45: 2367-75.
4. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014; 40: 523-32. doi:10.1016/j.ctrv.2013.11.006.
5. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Rev. 2010; 24: 191-9.
6. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369: 111-21.
7. Mayor S. Arsenic trioxide combination improves survival in APL. Lancet Oncol. 2013; 14: e346.
8. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012; 26: 1743-51.
9. Mann KK, Wallner B, Lossos IS, Miller WH, Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009; 18: 1727-34.
10. Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004; 93: 173-87.
11. Wang Y, Wei Y, Zhang H, Shi Y, Li Y, Li R. Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase. Med Oncol. 2012; 29: 1328-34.
12. Zhang H, Su X, Guo L, Zhong L, Li W, Yue Z, et al. Silencing SATB1 Inhibits the Malignant Phenotype and Increases Sensitivity of Human Osteosarcoma U2OS Cells to Arsenic Trioxide. Int J Med Sci. 2014; 11: 1262-9. doi:10.7150/ijms.10038.
13. Andoh Y, Suzuki H, Araki M, Mizutani A, Ohashi T, Okumura T, et al. Lowand high-level expressions of heme oxygenase-1 in cultured cells under uninduced conditions. Biochem Biophys Res Commun. 2004; 320: 722-9. doi:10.1016/j.bbrc.2004.05.212.
14. Maines MD, Gibbs PE. 30 some years of heme oxygenase: from a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. Biochem Biophys Res Commun. 2005; 338: 568-77. doi:10.1016/j.bbrc.2005.08.121.
15. Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle. 2012; 11: 2248-52.
16. Zhong L, Wang Y, Li W, Gu J, Li X, Wang X, et al. Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide. Mol Cell Biochem. 2014; 392: 135-44. doi:10.1007/s11010-014-2027-1.
17. Shi Y, Wei Y, Qu S, Wang Y, Li Y, Li R. Arsenic induces apoptosis of human umbilical vein endothelial cells through mitochondrial pathways. Cardiovasc Toxicol. 2010; 10: 153-60.
18. Ramprasath T, Vasudevan V, Sasikumar S, Puhari SS, Saso L, Selvam GS. Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases. Curr Top Med Chem. 2015; 15: 857-71.
19. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014; 39: 199-218. doi:10.1016/j.tibs.2014.02.002.
20. Sanchez Y, Calle C, de Blas E, Aller P. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. Chem Biol Interact. 2009; 182: 37-44.
21. Wang Y, Xu Y, Wang H, Xue P, Li X, Li B, et al. Arsenic induces mitochondria-dependent apoptosis by reactive oxygen species generation rather than glutathione depletion in Chang human hepatocytes. Arch Toxicol. 2009; 83: 899-908.
22. Das J, Ghosh J, Manna P, Sinha M, Sil PC. Taurine protects rat testes against NaAsO(2)-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol Lett. 2009; 187: 201-10.
23. Gambari R. New trends in the development of transcription factor decoy (TFD) pharmacotherapy. Curr Drug Targets. 2004; 5: 419-30.
24. Xu X, Zhang Y, Li W, Miao H, Zhang H, Zhou Y, et al. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol. 2014; 92: 220-34. doi:10.1016/j.bcp.2014.09.008.
25. Cheng ZG, Zhang GD, Shi PQ, Du BS. Expression and antioxidation of Nrf2/ARE pathway in traumatic brain injury. Asian Pac J Trop Med. 2013; 6: 305-10. doi:10.1016/s1995-7645(13)60061-9.
26. Mann GE, Niehueser-Saran J, Watson A, Gao L, Ishii T, de Winter P, et al. Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao. 2007; 59: 117-27.
27. Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, et al. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol. 2014; 274: 293-301. doi:10.1016/j.taap.2013.10.026.
28. Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M, Zhang DD, et al. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol. 2014; 7: 1502-13.